<div xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://hl7.org/fhir ../../src-generated/schemas/fhir-single.xsd">
   <blockquote class="fhir-version-note">
      <p>
      This Implementation Guide is designed to use the R4 version of the HL7&#174; FHIR&#174; standard.<br /> 
      For information on submitting to our Direct FHIR endpoints using FHIR STU3, see the 
      <a href="CIBMTR_Direct_FHIR_API_Connection_Guide_STU3.pdf">Direct FHIR for STU3 Guide</a>.
      </p>
  </blockquote>
 <p>
  This FHIR Implementation Guide (IG) describes how to send data to CIBMTR via HL7&#174; FHIR&#174;.   
  </p>
  <a name="Introduction"> </a>
  <h3>Introduction</h3>
  <p>
  The <a href="https://www.cibmtr.org">Center for International Blood &amp; Marrow Transplant Research速 (CIBMTR速)</a>
  is a research collaboration between the <a href="https://bethematch.org/">National Marrow Donor Program速 (NMDP)/Be The Match速</a> 
  and the <a href="https://www.mcw.edu/">Medical College of Wisconsin (MCW)</a>. 
  The CIBMTR collaborates with the global scientific community to advance hematopoietic cell 
  transplantation (HCT) and other cellular therapy worldwide to increase survival and enrich 
  quality of life for patients. 
  </p>
  <p>
  The CIBMTR facilitates critical observational and interventional research through scientific 
  and statistical expertise, a large network of transplant centers, and a unique and extensive clinical outcomes database.
  CIBMTR collects data for HCT recipients using a web-based manual data entry system 
  (<a href="https://www.cibmtr.org/DataManagement/SystemApplications/FormsNet3">FormsNet</a>) 
  and an automated messaging system 
  (<a href="https://www.cibmtr.org/DataManagement/SystemApplications/AGNIS/Pages/default.aspx">A Growable Network Information System (AGNIS)</a>).
  </p>
  <p>
  CIBMTR is now collecting data through the <a href="http://hl7.org/fhir">HL7 Fast Healthcare Interoperability Resources&#174; (FHIR&#174;)</a> standard. 
  This IG describes the technical specification that CIBMTR accepts from third party clients producing FHIR resources for reporting HCT data.
  It is primarily based on the <a href="https://www.hl7.org/fhir/us/core/">US Core FHIR IG</a> which defines the minimum conformance 
  requirements for accessing patient data. 
  </p>
  <p>
  Initially, this IG is focused on information required for sending Patient demographic data that is necessary for creating or retrieving a CIBMTR 
  Research ID (CRID), and for reporting Patient resources with a known CRID. We have also begun specifying a profile for reporting laboratory observations,
  focusing on a set of variables that have been identified as a priority for the CIBMTR Data Transformation Initiative in Fiscal Year 2022. And we have 
  begun describing how medication-related resources may be reported, specifically in the context of CIBMTR Form 2400.
  </p>

  <a name="Guidance"> </a>
  <h3>Guidance</h3>
  <ul>
    <li><a href="Connection-Guide-R4.html">Connecting and Access</a></li>
    <li><a href="Endpoints.html">API Endpoints</a></li>
    <li><a href="Access-Credentials.html">Access Credentials</a></li>
    <li><a href="CRID-Assignment.html">CRID Assignment</a></li>
    <li><a href="Laboratory-Observations.html">Laboratory Observations</a></li>
    <li><a href="Medications.html">Medications</a></li>
    <li><a href="Bundles.html">Bundles</a></li>
    <li><a href="Example-Code.html">Example code</a></li>
  </ul>

  <a name="Artifacts"> </a>
  <h3>Highlighted Artifacts</h3>
  <a name="Profiles"> </a>
  <h4>Profiles</h4>
  <ul>
    <li><a href="StructureDefinition-cibmtr-patient.html">CIBMTR Patient</a></li>
    <li><a href="StructureDefinition-cibmtr-observation-lab.html">Laboratory Observation Results</a></li>
      <ul>
        <li><a href="StructureDefinition-cibmtr-obs-priority-variables.html">Laboratory Observation for Priority Variables</a></li>
      </ul>
    <li><a href="StructureDefinition-cibmtr-medication-request.html">MedicationRequest</a></li>
    <li><a href="StructureDefinition-cibmtr-medication.html">Medication</a></li>
      <ul>
        <li><a href="StructureDefinition-cibmtr-mobilizing-agent-medication.html">Mobilizing Agent Medication</a></li>
        <li><a href="StructureDefinition-cibmtr-prep-regimen-medication.html">Preprative Regimen Medications</a></li>
        <li><a href="StructureDefinition-cibmtr-additional-peri-transplant-medication.html">Additional Drugs in Peri-Transplant Period</a></li>
        <li><a href="StructureDefinition-cibmtr-gvhd-prophylaxis-medication.html">GVHD Prophylaxis Medication</a></li>
        <li><a href="StructureDefinition-cibmtr-post-hct-disease-therapy-planned-medication.html">Planned Post-HCT Disease Therapy Medication</a></li>
        <li><a href="StructureDefinition-cibmtr-prior-exposure-medication.html">Prior Exposure Medication</a></li>
     </ul>
  </ul>

  <a name="ValueSets"></a>
  <h4>ValueSets</h4>
  <ul>
    <li>LOINC (used with Observation)</li>
      <ul>
          <li><a href="ValueSet-cibmtr-priority-variables-2022.html">CIBMTR Priority Variables for FY22</a></li>
      </ul>
    <li>RxNorm (used in MedicationRequest and Medication)</li>
      <ul>
        <li><a href="ValueSet-med-mobilizing-agents-vs.html">Mobilizing Agents (auto only)</a></li>
        <li><a href="ValueSet-med-prep-regimen-vs.html">Prep Regimen</a></li>
        <li><a href="ValueSet-med-addition-peri-transplant-vs.html">Additional Drugs in Peri-Transplant Period</a></li>
        <li><a href="ValueSet-med-gvhd-prophylaxis-vs.html">GVHD Prophylaxis</a></li>
        <li><a href="ValueSet-med-post-hct-disease-therapy-planned-vs.html">Post-HCT Disease Therapy Planned</a></li>
        <li><a href="ValueSet-med-prior-exposure-vs.html">Prior Exposure: Potential Study Eligibility</a></li>
        <li><a href="ValueSet-med-all-form2400-vs.html">All Form 2400 Medications</a></li>
      </ul>
  </ul>
</div>